Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1524893 | 1.00 | HTR3A (0.31) | HTR3AHRH4NOS3NOS1NOS2 | |
| SCHEMBL2708905 | 0.97 | — | — | |
| SCHEMBL1524762 | 0.91 | HTR3A (0.39) | HTR3AHRH4NOS3NOS1NOS2 | |
| SCHEMBL15552104 | 0.91 | HTR3A (0.39) | HTR3AHRH4NOS3NOS1NOS2 | |
| SCHEMBL6585017 | 0.91 | HTR3A (0.39) | HTR3AHRH4NOS3NOS1NOS2 | |
| SCHEMBL23611455 | 0.91 | HTR3A (0.34) | HTR3AHRH4NOS1NOS2 | |
| SCHEMBL2334878 | 0.91 | HTR3A (0.39) | HTR3AHRH4NOS3NOS1NOS2 | |
| SCHEMBL1524741 | 0.91 | HTR3A (0.39) | HTR3AHRH4NOS3NOS1NOS2 | |
| SCHEMBL1057638 | 0.90 | — | — | |
| SCHEMBL6696059 | 0.88 | HTR3A (0.35) | HTR3AHRH4NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130085133-A1 | ANTI-VIRAL TREATMENT AND ASSAY TO SCREENFOR ANTI-VIRAL AGENT | Sourthern Research Institute Office of Commercialization and Intellectual Prop. (US) | 2013-04-04 | — | — | US | disclosed |
| WO-2011097607-A1 | ANTI-VIRAL TREATMENT AND ASSAY TO SCREEN FOR ANTI-VIRAL AGENT | SOUTHERN RESEARCH INSTITUTE (US) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085133-A1 | ANTI-VIRAL TREATMENT AND ASSAY TO SCREENFOR ANTI-VIRAL AGENT | MAVS, SNRPE, LONP1 | HTR3A 4475/4885HRH4 2343/4885NOS3 2966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.